18 April 2018

Scancell Holdings plc

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, has raised £7.5 million through an institutional placing of shares.

LGB Corporate Finance worked closely with the company and its corporate broker, Panmure Gordon, to extend distribution of the issue to a number of wealth management, family office and private investors.

The proceeds of the placing will be used to commence scheduled trials of a vaccine addressing late stage melanoma, support the Cancer Research UK development of the company vaccine against non-small-cell lung carcinoma, commence a first in-human study in patients with triple-negative breast cancer, further the company’s collaboration with BioNTech and initiate a pre-clinical development programme for oesophageal, gastric, pancreatic and colorectal cancers.  These projects demonstrate the broadening scope of the company’s business and its collaborations with tier-1 counterparties in the immuno oncology sector.

Recent Articles

26 November 2019

FCA Introduces Restrictions on the Distribution of Mini-bonds

You may have seen the reports of the FCA’s restrictions on the marketing of so-called speculative mini-bonds to retail investors in the wake of the LCF scandal, in which bonds, mass-marketed to retail investors, were used to lend on to Read more

News & Insights

26 November 2019

LGB arranges £25m MTN programme for 1pm plc

LGB Corporate Finance arranges a £25 million medium term note (MTN) programme for 1pm plc, the AIM quoted independent specialist finance provider.

Read more


6 November 2019

5 Top Tips On How To Sell A Business

Angus Grierson, Managing Director of LGB Corporate Finance, wrote an article for CEO Today on the top five tips to selling your business amid a globally uncertain backdrop.

Read more

News & Insights